Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.58 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856542 | 1.00 | NOS2 (0.58) | NOS2ACACBTACR1ATMPYGL | |
| SCHEMBL29469535 | 1.00 | NOS2 (0.58) | NOS2ACACBTACR1ATMPYGL | |
| SCHEMBL2854351 | 0.88 | TACR1 (0.55) | NOS2ACACBTACR1ALDH1A1THRB | |
| SCHEMBL2854353 | 0.88 | TACR1 (0.55) | NOS2ACACBTACR1ALDH1A1THRB | |
| SCHEMBL15498913 | 0.88 | ATM (0.50) | NOS2TACR1ATMALDH1A1THRB | |
| SCHEMBL2859969 | 0.87 | ACACB (0.53) | NOS2ACACBTACR1ALDH1A1 | |
| SCHEMBL2859966 | 0.87 | ACACB (0.53) | NOS2ACACBTACR1ALDH1A1 | |
| SCHEMBL17176127 | 0.86 | ATM (0.63) | NOS2ACACBTACR1ATMALDH1A1 | |
| SCHEMBL3050135 | 0.86 | NPSR1 (0.61) | TACR1ATMALDH1A1KMT2ANPSR1 | |
| SCHEMBL315117 | 0.86 | NPSR1 (0.61) | TACR1ATMALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758844-B1 | PHOSPHINE-PHOSPHORAMIDITE COMPOUNDS | JOHNSON MATTHEY PLC (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-1346971-B1 | Production method for biarylalanine | SUMITOMO CHEMICAL CO (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-1758844-A1 | PHOSPHINE-PHOSPHORAMIDITE COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| WO-2006012045-A1 | PHOSPHINE-PHOSPHORAMIDITE COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1330464-B1 | PHOSPHINO-AMINOPHOSPHINES, CATALYST COMPLEXES AND ENANTIOSELECTIVE HYDROGENATION | EASTMAN CHEM CO (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6906212-B1 | Phosphine-phosphoramidite compounds | EASTMAN CHEMICAL COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-1330464-A2 | PHOSPHINO-AMINOPHOSPHINES, CATALYST COMPLEXES AND ENANTIOSELECTIVE HYDROGENATION | EASTMAN CHEMICAL COMPANY (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6590115-B2 | Useful as ligands for metal catalysts for asymmetric reactions, in particular as rhodium complexes for asymmetric hydrogenation of enamide, itaconate, and alpha-ketoester compounds | EASTMAN CHEMICAL COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020065417-A1 | Useful as ligands for metal catalysts for asymmetric reactions, in particular as rhodium complexes for asymmetric hydrogenation of enamide, itaconate, and alpha-ketoester compounds | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2002-05-30 | — | — | US | disclosed |
| WO-2002026750-A2 | PHOSPHINO-AMINOPHOSPHINES, CATALYST COMPLEXES AND ENANTIOSELECTIVE HYDROGENATION | EASTMAN CHEMICAL COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | NOS2 421/4885ACACB 2960/4885TACR1 2442/4885 |
| US-20020065417-A1 | Useful as ligands for metal catalysts for asymmetric reactions, in particular as rhodium complexes for asymmetric hydrogenation of enamide, itaconate, and alpha-ketoester compounds | NOTUM, WEE1, WEE2 | NOS2 1617/4885ACACB 1928/4885TACR1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.